[
  {
    "ts": null,
    "headline": "DexCom (DXCM): Valuation in Focus After Q2 Revenue Beat and Cautious Outlook on Sector Tensions",
    "summary": "DexCom (DXCM) shares are in the spotlight after the company delivered better-than-expected second quarter revenues. However, a softer full-year outlook has drawn investor caution. Sector-wide trade tensions have also impacted sentiment. See our latest analysis for DexCom. DexCom’s share price has lost some momentum lately, reflecting both sector-wide pressure from US-China trade uncertainty and a cautious full-year outlook that overshadowed its quarterly revenue beat. While the 1-year total...",
    "url": "https://finnhub.io/api/news?id=b7c4df9fdcfaf3c0dbb412e4f3e3f336a6f05c79df557b62799f4e9bed1e5c24",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760480026,
      "headline": "DexCom (DXCM): Valuation in Focus After Q2 Revenue Beat and Cautious Outlook on Sector Tensions",
      "id": 137096000,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "DexCom (DXCM) shares are in the spotlight after the company delivered better-than-expected second quarter revenues. However, a softer full-year outlook has drawn investor caution. Sector-wide trade tensions have also impacted sentiment. See our latest analysis for DexCom. DexCom’s share price has lost some momentum lately, reflecting both sector-wide pressure from US-China trade uncertainty and a cautious full-year outlook that overshadowed its quarterly revenue beat. While the 1-year total...",
      "url": "https://finnhub.io/api/news?id=b7c4df9fdcfaf3c0dbb412e4f3e3f336a6f05c79df557b62799f4e9bed1e5c24"
    }
  },
  {
    "ts": null,
    "headline": "DexCom Inc. stock outperforms competitors on strong trading day",
    "summary": "DexCom Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=e71f67ce628523e7d8e277bc8e8e751c1b22e3bfcdc75fb09d2886cd27a0144e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760461320,
      "headline": "DexCom Inc. stock outperforms competitors on strong trading day",
      "id": 137149186,
      "image": "",
      "related": "DXCM",
      "source": "MarketWatch",
      "summary": "DexCom Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=e71f67ce628523e7d8e277bc8e8e751c1b22e3bfcdc75fb09d2886cd27a0144e"
    }
  },
  {
    "ts": null,
    "headline": "2 Stocks Down 17% and 21% to Buy Right Now",
    "summary": "Both companies have faced recent challenges, but look likely to overcome them.",
    "url": "https://finnhub.io/api/news?id=d49eb3614f713d416b74bef8d3d4948680b4c2c7425babaf0d026c26e1e28ea2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760450400,
      "headline": "2 Stocks Down 17% and 21% to Buy Right Now",
      "id": 137086167,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "Both companies have faced recent challenges, but look likely to overcome them.",
      "url": "https://finnhub.io/api/news?id=d49eb3614f713d416b74bef8d3d4948680b4c2c7425babaf0d026c26e1e28ea2"
    }
  },
  {
    "ts": null,
    "headline": "Has DexCom’s Latest 14.5% Drop Created an Opportunity for Investors in 2025?",
    "summary": "If you’re trying to figure out whether now’s the time to buy, hold, or even sell DexCom stock, you’re not alone. After all, its share price has been a bit of a roller coaster lately. Over the last month, DexCom dropped 14.5%, extending a slide that’s seen the stock down 16.9% year-to-date and off more than 34% from its highs of the past few years. It’s not all bad news, though. Alongside shifting market dynamics around growth and risk, the most recent 1.7% weekly dip could be sparking new...",
    "url": "https://finnhub.io/api/news?id=579271b23dc05ee7c513da722d1a6354976b028e054c952ee02fc15128035009",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760440053,
      "headline": "Has DexCom’s Latest 14.5% Drop Created an Opportunity for Investors in 2025?",
      "id": 137086383,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "If you’re trying to figure out whether now’s the time to buy, hold, or even sell DexCom stock, you’re not alone. After all, its share price has been a bit of a roller coaster lately. Over the last month, DexCom dropped 14.5%, extending a slide that’s seen the stock down 16.9% year-to-date and off more than 34% from its highs of the past few years. It’s not all bad news, though. Alongside shifting market dynamics around growth and risk, the most recent 1.7% weekly dip could be sparking new...",
      "url": "https://finnhub.io/api/news?id=579271b23dc05ee7c513da722d1a6354976b028e054c952ee02fc15128035009"
    }
  },
  {
    "ts": null,
    "headline": "Artisan Mid Cap Fund Q3 2025 Commentary",
    "summary": "Global equities continued to climb in Q3, finishing the period with double-digit year-to-date gains. Read more here.",
    "url": "https://finnhub.io/api/news?id=335246dbc5e6017bf79a3d9dca9caa2f586a6e2a5780ba11d8a74c55f8339d9a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760425200,
      "headline": "Artisan Mid Cap Fund Q3 2025 Commentary",
      "id": 137076046,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1972340844/image_1972340844.jpg?io=getty-c-w1536",
      "related": "DXCM",
      "source": "SeekingAlpha",
      "summary": "Global equities continued to climb in Q3, finishing the period with double-digit year-to-date gains. Read more here.",
      "url": "https://finnhub.io/api/news?id=335246dbc5e6017bf79a3d9dca9caa2f586a6e2a5780ba11d8a74c55f8339d9a"
    }
  },
  {
    "ts": null,
    "headline": "Q2 Earnings Roundup: DexCom (NASDAQ:DXCM) And The Rest Of The Patient Monitoring Segment",
    "summary": "Let’s dig into the relative performance of DexCom (NASDAQ:DXCM) and its peers as we unravel the now-completed Q2 patient monitoring earnings season.",
    "url": "https://finnhub.io/api/news?id=428bc39afd436c8055100b231f14c13dcedfd7fb7e77505eb8bbcff4ca2dea48",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760412668,
      "headline": "Q2 Earnings Roundup: DexCom (NASDAQ:DXCM) And The Rest Of The Patient Monitoring Segment",
      "id": 137086384,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "Let’s dig into the relative performance of DexCom (NASDAQ:DXCM) and its peers as we unravel the now-completed Q2 patient monitoring earnings season.",
      "url": "https://finnhub.io/api/news?id=428bc39afd436c8055100b231f14c13dcedfd7fb7e77505eb8bbcff4ca2dea48"
    }
  }
]